Peter MacCallum Cancer Centre,
Melbourne, Australia

Associate Professor Shahneen Sandhu is a consultant medical oncologist and a leading clinician researcher with a full time appointment in the melanoma/skin and uro-oncology units at the Peter MacCallum Centre, Melbourne. Her research is currently focused on the design, conduct and analysis of early clinical trials with novel drugs that aim to co-develop predictive biomarkers in conjunction with therapeutics in order to personalise treatment and improve patient outcome. Her training and research experience have provided her with a diverse range of skills in the conduct of clinical and translational research studies. She has led trials from phase I concept development all the way to registration of the compound and companion diagnostic for optimal patient selection. She currently leads several multicentre investigator-initiated trials and multiple collaborative biomarker translational projects evaluating the immune landscape in melanoma, merkel cell carcinoma and prostate cancer. Associate Professor Sandhu has >187 peer reviewed publications including, 39 first or last author publications in premier journals such as New England Journal of Medicine, Nature Biotech, Cancer Discovery, Lancet Oncology, Journal of Clinical Oncology, Nature Review Cancers, European Urology, Clinical Cancer Research, European Journal of Cancer, Annals of Oncology, etc. This work has largely focused on the development of Poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian, breast and prostate cancer, evaluating immunotherapy combination therapies and immune related toxicities and developing prognostic and predictive circulating biomarkers (circulating tumour cells, circulating tumour DNA, mRNA) in prostate cancer and melanoma.